T4260 |
Capmatinib 2HCl
|
1197376-85-4
|
100%
|
|
INCB-28060(free base) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.INCB28060 exhibits picomolar enzymatic potency and is highl...
|
T2208 |
Bacitracin Zinc
|
1405-89-6
|
63.98%
|
|
Bacitracin Zinc is an antibiotic that interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, interference for inhibition of cleavage of Tyr from M...
|
T5677 |
SAR125884 hydrochlorid (1116743-46-4(free base))
|
T5677
|
95%
|
|
SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).
|
T39507L |
Fosgonimeton acetate
|
|
97.05%
|
|
Fosgonimeton aceate is an agonist of hepatocyte growth factor (HGF).
|
T6095 |
JNJ-38877605
|
943540-75-8
|
97.15%
|
|
JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
|
T3274 |
S49076
|
1265965-22-7
|
97.4%
|
|
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.
|
T6907 |
NPS-1034
|
1221713-92-3
|
97.86%
|
|
NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
|
T7376 |
Dihexa
|
1401708-83-5
|
98%
|
|
Dihexa is an activator of the hepatocyte growth factor/c-Met (HGF/c-Met) system,it binds to HGF (Kd = 65 pM),and an analog of the peptide angiotensin IV.
|
T5656 |
(±)-Norcantharidin
|
29745-04-8
|
98%
|
|
Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
|
T6517 |
Golvatinib
|
928037-13-2
|
98%
|
|
Golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-...
|
TQ0210 |
Savolitinib
|
1313725-88-0
|
98.03%
|
|
Savolitinib (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).
|
T3550 |
X-376
|
1365267-27-1
|
98.29%
|
|
Ensartinib (X-396) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic...
|
T5467 |
SAR125844
|
1116743-46-4
|
98.39%
|
|
SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)
|
T2676 |
PF-04217903
|
956905-27-4
|
98.55%
|
|
MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.
|
T2680 |
NVP-BVU972
|
1185763-69-2
|
98.61%
|
|
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
|
T4332 |
C-Kit-IN-1
|
1225278-16-9
|
98.72%
|
|
DCC-2618 is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).
|
T1797 |
Cabozantinib S-malate
|
1140909-48-3
|
98.87%
|
|
Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential a...
|
T2282 |
RPI-1
|
269730-03-2
|
98.91%
|
|
RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
|
T6260 |
AMG-208
|
1002304-34-8
|
99.12%
|
|
AMG 208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
|
T13108 |
Pamufetinib
|
1190836-34-0
|
99.15%
|
|
TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectivel...
|